Zileuton is an orally active inhibitor of 5-lipoxygenase, an enzyme involved in the synthesis of leukotrienes. By inhibiting leukotriene formation, Zileuton helps reduce inflammation, bronchoconstriction, and other symptoms associated with asthma. It is primarily used for the maintenance treatment of asthma and is not indicated for acute asthma attacks. Zileuton was introduced in 1996 by Abbott Laboratories and is marketed under the brand names Zyflo and Zyflo CR by Cornerstone Therapeutics Inc.
During the production and storage of Zileuton, related compounds and impurities may form, which must be controlled to ensure the medication’s safety and efficacy. Regulatory authorities provide stringent guidelines for monitoring these impurities.
Key aspects of Zileuton-related compounds and impurities include:
Advanced analytical techniques, such as High-Performance Liquid Chromatography (HPLC), are used to detect and quantify Zileuton-related compounds and impurities, ensuring compliance with quality standards.
Patients taking Zileuton should have their liver function monitored regularly, as the medication may cause liver enzyme elevations. Alcohol consumption should be limited to reduce the risk of liver toxicity. Inform your doctor of any pre-existing liver conditions or medications you are taking.
A serious adverse effect of Zileuton is liver toxicity, which may manifest as elevated liver enzymes or, in rare cases, jaundice. Regular monitoring of liver function tests is crucial to mitigate this risk.
Patients on Zileuton should monitor their liver function through regular blood tests. Additionally, any symptoms of liver dysfunction, such as fatigue, abdominal pain, or yellowing of the skin or eyes, should be reported to a healthcare provider immediately.
Zileuton has a duration of action of approximately 12 hours, which is why it is typically prescribed to be taken twice daily for optimal asthma maintenance.
